Menghao Shi,1 Xiufeng Zhao,2 Jiulong Zhang,1 Shuang Pan,1 Chunrong Yang,3 Ying Wei,1 Haiyang Hu,1 Mingxi Qiao,1 Dawei Chen,1 Xiuli Zhao1 1Department of pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China; 2Oncology Department, Affiliated Hongqi Hospital of Mudanjiang Medical College, Mudanjiang 157000, PR China; 3Department of pharmaceutics, School of Pharmacy, Jiamusi University, Jiamusi, Heilongjiang 154007, PR China Introduction: Specific polo-like kinase (PLK1) silencing with small interface RNA (siRNA) may be an effective approach for PLK1-overexpressed lung cancer. However, low siRNA concentration into cytoplasm of tumor tissue severely limits its application.Materials and methods: In thi...
Recently, RNA interfering (RNAi) has become a promising approach for cancer therapy. However, the ap...
Nowadays, the downregulation of genes involved in the pathogenesis of severe lung diseases through l...
Pei-Yao Xu,1,2 Ranjith Kumar Kankala,1–3 Yu-Jing Pan,1,2 Hui Yuan,1,2 Shi-Bin Wang,1–3 A...
Small interfering RNA (siRNA) therapies have been hampered by lack of delivery systems in the past d...
Pulmonary co-delivery to the lungs offers a potential therapy for pulmonary diseases. In this study,...
The clinical success of therapeutics of small interfering RNA (siRNA) is still hindered by its deliv...
Mingji Jin,1 Guangming Jin,2 Lin Kang,1 Liqing Chen,1 Zhonggao Gao,1 Wei Huang11State Key Laboratory...
Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than 15% eve...
A pulmonary codelivery system that can simultaneously deliver doxorubicin (DOX) and Bcl2 siRNA to th...
In this study, the anticancer activities of two siRNA carriers were compared using a human lung aden...
Gene silencing using small interfering RNA (siRNA) has shown significant potential in the treatment ...
Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The u...
Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The u...
Although surface PEGylation of siRNA vectors is effective for preventing protein adsorption and ther...
Recently, RNA interfering (RNAi) has become a promising approach for cancer therapy. However, the ap...
Recently, RNA interfering (RNAi) has become a promising approach for cancer therapy. However, the ap...
Nowadays, the downregulation of genes involved in the pathogenesis of severe lung diseases through l...
Pei-Yao Xu,1,2 Ranjith Kumar Kankala,1–3 Yu-Jing Pan,1,2 Hui Yuan,1,2 Shi-Bin Wang,1–3 A...
Small interfering RNA (siRNA) therapies have been hampered by lack of delivery systems in the past d...
Pulmonary co-delivery to the lungs offers a potential therapy for pulmonary diseases. In this study,...
The clinical success of therapeutics of small interfering RNA (siRNA) is still hindered by its deliv...
Mingji Jin,1 Guangming Jin,2 Lin Kang,1 Liqing Chen,1 Zhonggao Gao,1 Wei Huang11State Key Laboratory...
Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than 15% eve...
A pulmonary codelivery system that can simultaneously deliver doxorubicin (DOX) and Bcl2 siRNA to th...
In this study, the anticancer activities of two siRNA carriers were compared using a human lung aden...
Gene silencing using small interfering RNA (siRNA) has shown significant potential in the treatment ...
Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The u...
Small interfering RNA (siRNA) is effective in silencing critical molecular pathways in cancer. The u...
Although surface PEGylation of siRNA vectors is effective for preventing protein adsorption and ther...
Recently, RNA interfering (RNAi) has become a promising approach for cancer therapy. However, the ap...
Recently, RNA interfering (RNAi) has become a promising approach for cancer therapy. However, the ap...
Nowadays, the downregulation of genes involved in the pathogenesis of severe lung diseases through l...
Pei-Yao Xu,1,2 Ranjith Kumar Kankala,1–3 Yu-Jing Pan,1,2 Hui Yuan,1,2 Shi-Bin Wang,1–3 A...